Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: maceng2 who wrote (1462637)

6/13/2024 5:30:44 PM

From: Wharf Rat

2 Recommendations

Recommended By
Eric
pocotrader

Respond to of 1572768

"There are problems with the 'vaxxine'."

The problems are ideological, not medical. The only instances of mass deaths of children are in Ukraine and Gaza.

To: maceng2 who wrote (1462637)	6/13/2024 5:50:08 PM
From: Qone0	1 Recommendation Recommended By pocotrader Read Replies (2) \| Respond to of 1572768

There are no problems with the vax. The problem is the Mnra technology has to potential to cut the health care industry profits massively. When you can program your own immune system to kill cancer cells this happens. Didn't see this in any of your feeds did you? GSK plc (LSE/NYSE: GSK) today announced updated, longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center (MSK) evaluating Jemperli (dostarlimab) as a first-line treatment—as an alternative to surgery—for mismatch repair deficient (dMMR) locally advanced rectal cancer. The trial showed an unprecedented 100% clinical complete response rate (cCR) in 42 patients who completed treatment with dostarlimab, defined as complete pathologic response or no evidence of tumours as assessed by magnetic resonance imaging, endoscopy and digital rectal exam.